KUALA LUMPUR, July 5 – Dupixent® (Dupilumab) is the latest biologic treatment to be approved in Malaysia as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe CRSwNP, and whose disease is not adequately controlled with existing systemic corticosteroids and/ or surgery.
“CRSwNP is a chronic disease of the upper airway that obstructs the sinuses and nasal passages and Dupixent, as an add-on therapy to intranasal corticosteroid, can help to control persistent, often debilitating symptoms such as nasal congestion, difficulty breathing and loss of smell that can severely impact quality of life.
“As some patients find insufficient relief from existing forms of treatment, this approval is a significant milestone for patients with severe CRSwNP and offers Malaysians an effective new option,” said Quek Wee Ling, General Manager, Specialty Care (Thailand, Malaysia, Singapore & Vietnam) at Sanofi.
Prior to this approval, common treatment options for CRSwNP were limited to intranasal and systemic corticosteroids and surgery. However, for some patients, associated symptoms and recurrence of nasal polyps can occur, presenting a challenge that can now be addressed with the use of Dupixent (MAL 19056001AZ).
“We hope to fulfil the unmet needs of patients affected by these diseases in time to come.”
(KKLIU 1291 / EXP 31.12.2025)
